Caixin
Apr 18, 2022 07:53 PM
BUSINESS

China Drugmaker Plunges After Wanda Scion Doubts Covid Medicine Efficacy

Photo: VCG
Photo: VCG

(Bloomberg) — Shares of a traditional Chinese medicine-maker plunged by the daily limit after the son of one of China’s richest men questioned the efficacy of its drug commonly used to treat mild cases of Covid-19 in China.

Shijiazhuang Yiling Pharmaceutical Co. Ltd. fell by 10% in Shenzhen on Monday after Wang Sicong — Dalian Wanda Group Co. Ltd. Chairman Wang Jianlin’s son — reposted a video late last week on Weibo that questioned whether the World Health Organization had ever recommended the firm’s drug as Covid-19 treatment. The city of Shanghai has been distributing the medicine to its residents as the financial hub battles the virus outbreak.

You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code